drugset / Trial / NCT06003075
Induction Chemo-Nivo in Unresectable Stage III NSCLC
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the response rate, safety, and effectiveness of a combination therapy in patients with lung cancer.
Timeline
- Start
- 2023-12-13
- Primary completion
- 2024-07-05
- Completion
- 2024-07-05
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | carbo | Unknown | — | — |
| Subject | cis | Unknown | — | — |